Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

Market Cap	36.20B
Revenue (ttm)	25.21B
Net Income (ttm)	1.38B
Shares Out	1.63B
EPS (ttm)	0.85
PE Ratio	26.06
Forward PE	14.99
Dividend	0.47 (2.12%)
Ex-Dividend Date	Oct 11, 2024

Volume	9,940,527
Average Volume	16,274,098
Open	22.01
Previous Close	22.18
Day's Range	21.91 - 22.41
52-Week Range	15.68 - 25.90
Beta	0.64
RSI	68.99
Earnings Date	Jul 25, 2025

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection for endotracheal intubation, and general anesthesia using artificial respiration; remifentanil hydrochloride for Injection for induction and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients requiring opioid analgesia; nabuphine hydrochloride injection for induction of anesthesia; alfentanil hydrochloride injectio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 17,650
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600079

Financial Performance

In 2024, SHA:600079's revenue was 25.44 billion, an increase of 3.71% compared to the previous year's 24.52 billion. Earnings were 1.33 billion, a decrease of -37.70%.